Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
To the Editor: In the new Bethesda Consensus
Guidelines,1 HPV DNA testing is the "preferred"
approach to evaluating ASC-US when liquid-based cytology is used for screening.
Human papillomavirus testing is an attractive alternative to colposcopy and
detects most cases of cervical intraepithelial neoplasia (CIN) 2 or higher
without subjecting all women with ASC-US to colposcopy.2
Most clinicians, however, perform repeat cytologic testing 3 to 6 months after
a single ASC-US result.3 The differences
between HPV testing vs repeat cytology, therefore, require scrutiny.
Sawaya GF, Smith-McCune K. Testing for Human Papillomavirus in Women With Abnormal Pap Smear Results. JAMA. 2002;288(11):1350. doi:10.1001/jama.288.11.1350